Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
RydaptⓇ - Multi-targeted kinase inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03591510 (CPKC412A2218)
Acute myeloid leukemia
Phase 2
50
Occurrence of dose limiting toxicities
Event Free Survival (EFS)
Chemotherapy followed by Midostaurin
Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia
(AML)
Target Patients
Read-out Milesstone(s)
2025
Publication
TBD
112 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation